TY - CHAP M1 - Book, Section TI - Pharmacogenetics A1 - Cavallari, Larisa H. A1 - Lam, Y. W. Francis A2 - DiPiro, Joseph T. A2 - Yee, Gary C. A2 - Posey, L. Michael A2 - Haines, Stuart T. A2 - Nolin, Thomas D. A2 - Ellingrod, Vicki Y1 - 2020 N1 - T2 - Pharmacotherapy: A Pathophysiologic Approach, 11e AB - KEY CONCEPTS Genetic variation contributes to pharmacokinetic and pharmacodynamic drug properties. Genetic variation occurs for drug metabolism, drug transporter, and drug target proteins, as well as disease-associated proteins that may impact drug response. Single-nucleotide polymorphisms are the most common gene variations associated with drug response. Genetic polymorphisms may influence drug effectiveness and risk for toxicity. Pharmacogenetics is the study of the impact of genetic polymorphisms on drug response. The goals of pharmacogenetics are to optimize drug efficacy and limit drug toxicity based on an individual’s DNA. Gene therapy aims to cure disease caused by genetic defects by changing gene expression. Inadequate gene delivery and expression and serious adverse effects are obstacles to successful gene therapy. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1182422910 ER -